10-K: PURE Bioscience Reports FY25 Loss, Raises Capital

PURE Bioscience, Inc. reported a net loss of $2.4 million for fiscal year 2025, despite a slight increase in net product sales, and continues to rely on convertible debt financing from related parties.

Summary

• Reported a net loss of $2.4 million for the fiscal year ended July 31, 2025, compared to a net loss of $3.4 million in FY2024.
• Net product sales increased by $243,000 to $2.198 million in FY2025 from $1.955 million in FY2024, driven by increased sales in the food processing industry.
• Gross margin remained stable at 59% for both FY2025 and FY2024.
• Selling, general, and administrative expenses decreased by $722,000 to $3.259 million in FY2025.
• Used $2.015 million in cash from operating activities during FY2025, resulting in a cash balance of $334,000 as of July 31, 2025.
• Total liabilities increased to $6.174 million as of July 31, 2025, from $3.682 million in FY2024, primarily due to convertible note financings.
• Stockholders' deficiency increased to $5.116 million as of July 31, 2025, from $2.864 million in FY2024.
• Auditors expressed substantial doubt about the ability to continue as a going concern.
• Raised $2.0 million in principal through convertible promissory notes from accredited investors, including Board member Tom Y. Lee, during FY2025.
• One customer accounted for 18% of net product sales in FY2025.

Sentiment

Score: 3

Explanation: While there was a slight increase in revenue and a reduction in SG&A, the company continues to operate at a significant net loss, has negative cash flow from operations, and faces a 'going concern' doubt from its auditors. Its heavy reliance on related-party convertible debt for funding, coupled with customer concentration and regulatory approval delays, indicates a precarious financial position and high operational risks. The positive aspects are overshadowed by fundamental financial instability.

Positives

• Net product sales increased by $243,000 (12.4%) to $2.198 million in FY2025, driven by increased sales across the end-user network servicing the food processing industry.
• Gross margin remained strong and stable at 59% for both FY2025 and FY2024.
• Selling, general, and administrative expenses decreased by $722,000 in FY2025, primarily due to reduced personnel, facility, and board fees.
• Received $175,000 from the U.S. Government's Employee Retention Tax Credit Program in FY2025.
• SDC-based products (PURE Hard Surface, PURE Control) are registered with the EPA, FDA, and Health Canada, highlighting regulatory compliance and market access.
• SDC technology is described as a broad-spectrum, non-toxic antimicrobial agent with superior efficacy, reduced toxicity (Category IV by EPA), non-causticity, and the inability of bacteria to develop resistance.
• Holds twelve U.S. patents and registered trademarks for key brands, indicating a protected intellectual property portfolio.
• The 2024 Equity Incentive Plan was approved by shareholders, reserving 10,000,000 shares for awards, providing a mechanism for employee and director incentives.

Negatives

• Reported a net loss of $2.4 million for FY2025, continuing a history of losses and contributing to a cumulative net loss of $139.0 million as of July 31, 2025.
• Used $2.015 million in operating activities during FY2025, indicating ongoing cash burn and a low cash balance of $334,000.
• Auditors expressed 'substantial doubt about our ability to continue as a going concern' due to recurring losses and negative operating cash flows.
• Stockholders' deficiency increased to $5.116 million as of July 31, 2025, from $2.864 million in FY2024.
• Significant reliance on related-party financing; Tom Y. Lee, a Board member, invested $2.0 million in convertible notes during FY2025.
• Interest expense increased by $144,000 to $299,000 in FY2025, primarily due to accrued interest on outstanding convertible notes.
• One customer accounted for 18% of net product sales in FY2025, indicating customer concentration risk.
• Executive and non-employee director salaries/fees were voluntarily reduced during FY2025 and further reduced subsequent to July 31, 2025, reflecting financial constraints.
• Common stock is quoted on the OTCQB, which offers significantly less liquidity and may result in a reduced market price and difficulty obtaining financing.
• Has never paid dividends and does not anticipate doing so in the foreseeable future.
• SDC-based products are generally more expensive to produce than existing chemicals, which may deter customers despite superior efficacy.
• Has limited sales, marketing, and product distribution experience, with long and unpredictable sales cycles.
• Dependent on a single third-party manufacturer (Intercon Chemical Company) for SDC-based products, posing supply chain risk.
• Has not received required USDA approval to utilize PURE Control in OLR poultry processing, and there is no assurance of obtaining approvals for raw meats (beef and pork).

Risks

• Auditors expressed substantial doubt about the ability to continue as a going concern due to recurring losses and negative operating cash flows.
• Has limited capital and will need to raise additional capital in the future, which may not be available on acceptable terms or cause significant dilution to existing stockholders.
• Has a history of losses and may not achieve or maintain profitability.
• Raising additional funds by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders, restrict operations, or require relinquishing proprietary rights.
• Needs to continue to increase customer awareness and adoption of food safety product offerings, PURE Hard Surface and PURE Control.
• May not be able to correctly estimate future revenues and operating expenses, which could lead to cash shortfalls and require securing additional financing sooner than planned.
• Quarterly operating results may vary, which could negatively affect the market price of common stock.
• Inability to obtain required regulatory approvals from the FDA and USDA, or delays in such efforts, will harm the ability to commercialize PURE Control as a direct food contact processing aid.
• A loss of one or more key customers could adversely affect business, as one customer accounted for 18% of net product sales in FY2025.
• Dependent on core SDC technology; if efforts to achieve or maintain market acceptance are not successful, profitability is unlikely.
• Subject to intense competition in the food safety market from larger, more established competitors with greater resources and lower-cost alternatives.
• Has limited sales, marketing, and product distribution experience, leading to long and unpredictable sales cycles.
• Dependent on a third-party (Intercon Chemical Company) for manufacturing SDC-based products, over whom there is limited control, posing risks of supply interruption and quality issues.
• Relies on third parties to develop SDC-based products, and they may not do so successfully or diligently.
• Subject to substantial regulation related to quality standards; failure to comply could affect the ability to commercialize SDC products.
• The industries in which operates are heavily regulated, leading to time-consuming and expensive approval processes.
• Inability to obtain, maintain, or defend patent and other intellectual property rights relating to technology would materially adversely impact results of operations.
• May incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• Third parties may claim infringement of their proprietary rights, potentially preventing manufacturing and selling some products.
• Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.
• May be subject to claims that employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• The price of common stock has been and may continue to be volatile, exacerbated by its OTCQB listing.
• Potential sales or issuances of common stock to raise capital, or the perception of such sales, could cause dilution to current stockholders and the price of common stock to fall.
• Common stock is deemed to be penny stock, which may make it more difficult for investors to sell shares due to suitability requirements.
• Has never paid dividends on capital stock and does not anticipate paying any cash dividends in the foreseeable future.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control and could also limit the market price of stock.
• Compliance with the reporting requirements of federal securities laws can be expensive.
• Failure to maintain an effective system of internal controls could lead to inaccurate financial results or prevent fraud.
• Subject to tax audits by various tax authorities in multiple jurisdictions, which could result in material changes to financial results.
• May not be able to utilize all, or any, of its tax net operating loss carry-forwards due to ownership change limitations.

Future Outlook

The company expects to continue incurring losses in future periods and will need to raise additional capital to fund operations until it can consistently generate positive cash flow. Future capital requirements are dependent on market acceptance of products, sales and marketing costs, regulatory approvals, product development, customer orders, vendor payments, and intellectual property costs. Plans include expanding business operations and hiring additional sales and support personnel. Costs and delays in receiving necessary federal and state approvals for products are expected to increase. Future patent prosecution and defense efforts will primarily focus on North America, Europe, Asia, and Mexico. The Manufacturing Supply Agreement with Intercon Chemical Company is expected to be renewed in Fiscal 2026.

Management Comments

• We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control.
• Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC.
• We see significant market opportunities for our safe and effective SDC-based solutions, particularly in the food industry.
• Our goal is to establish a sustainable company by commercializing SDC-based products developed through our proprietary technology platform.
• We aim to deliver leading antimicrobial solutions that tackle food safety risks across the entire food industry supply chain.
• We believe our SDC-based products offer superior pathogen control compared to traditional chemical solutions, which often have higher toxicity.
• We believe we have successfully attracted skilled and experienced talent; however, the competition for qualified personnel is fierce, and we cannot guarantee our ability to retain or attract them in the future.
• We are committed to fostering a culture that promotes the values, behaviors, and attributes essential for advancing our business and executing our strategy.
• Our management has considerable discretion in the use of our cash.
• Our Board believes our leadership structure enhances the accountability of our Chief Executive Officer to the Board and encourages balanced decision making.

Industry Context

The U.S. food industry continues to rely on toxic chemicals as processing aids, facing increasing pathogen resistance and reduced efficacy. Traditional disinfectants typically fall into higher EPA toxicity categories (I and II), contrasting with SDC's Category IV (lowest toxicity) rating. The food safety market is highly competitive, dominated by larger, more established players with greater financial and technical resources, often offering lower-priced alternatives. Industry trends indicate consolidation among large food safety companies, intensifying competitive pressure. The biotechnology sector, where the company operates, is characterized by a proliferation of patents, leading to complex intellectual property challenges.

Comparison to Industry Standards

• SDC is rated in the lowest EPA toxicity category (Category IV), while traditional disinfectants (e.g., peracetic acid, acidified sodium chlorite, ozone, chlorine dioxide) typically fall into Categories I and II, indicating a superior safety profile for SDC-based products.
• PURE Hard Surface demonstrated a 96% improvement in efficacy compared to traditional quaternary ammonia-based sanitizers in in-store field testing on critical food contact areas, suggesting superior performance.
• PURE Control demonstrates superior efficacy with up to a 6 log reduction in Salmonella on treated poultry products, a strong performance metric for food processing aids.
• SDC-based products are generally more expensive to produce than existing chemical alternatives, which may deter customers despite superior efficacy, posing a challenge against industry cost standards.
• The company's dependence on a single third-party manufacturer (Intercon Chemical Company) for concentrated SDC-based products deviates from best practices for supply chain resilience, where multiple qualified suppliers are typically preferred to mitigate risks.

Management Changes

Corporate Governance

Legal Proceedings

• No material lawsuits against the company or its wholly-owned subsidiary as of July 31, 2025.
• May become involved in various lawsuits and legal proceedings in the ordinary course of business, which could be costly and substantially disrupt business.

Related Party Transactions

• Tom Y. Lee, a Board member, invested $2.0 million in the 2025 Private Placement of convertible promissory notes during FY2025.
• Tom Y. Lee invested $1.785 million in the 2024 Private Placement of convertible promissory notes during FY2024.
• Tom Y. Lee invested $1.0 million and Ivan Chen (Board member and Mr. Lee's nephew) invested $15,000 in the 2023 Private Placement of convertible promissory notes during FY2023.
• Subsequent to July 31, 2025, Tom Y. Lee invested $350,000 in the 2026 Private Placement of convertible promissory notes.
• As of July 31, 2025, accounts payable included $250,000 in board fees due to officers and directors.
• The company has a Related Party Transaction Policy and Procedures requiring Audit Committee or independent director consent for such transactions.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity issuances and convertible debt. No anticipated dividends mean returns are solely dependent on stock appreciation. The OTCQB listing and 'penny stock' designation limit liquidity and market appeal. Anti-takeover provisions could prevent beneficial change of control transactions.
• **Employees**: Executive officers experienced voluntary salary reductions, reflecting financial constraints. The 2024 Equity Incentive Plan provides a mechanism for long-term incentives, but competition for qualified personnel is fierce.
• **Customers**: Benefit from the continued development and commercialization of SDC-based products, which offer superior efficacy and lower toxicity compared to traditional solutions. However, higher product costs and long sales cycles may impact adoption.
• **Creditors**: Total liabilities have significantly increased, primarily due to convertible notes. The 'going concern' doubt raises concerns about the company's ability to repay debt without further capital raises.
• **Suppliers**: Dependence on a single third-party manufacturer (Intercon Chemical Company) for SDC concentrate creates a single point of failure, posing risks to supply chain stability and potentially impacting product availability.

Next Steps

• Increase customer awareness and adoption of PURE Hard Surface and PURE Control.
• Successfully complete in-plant validation trials and convert them into customer orders.
• Obtain required USDA approvals for PURE Control in OLR poultry processing and for raw meats (beef and pork).
• Develop additional proprietary products and applications.
• Protect and enhance intellectual property, focusing patent prosecution and defense in North America, Europe, Asia, and Mexico.
• Expand sales through distribution networks.
• Partner with third parties for SDC-based product approvals and commercialization outside the U.S.
• Leverage technology platform through licensing and distribution collaborations to create new products and explore additional markets.
• Raise additional capital to fund continuing operations.
• Expand business operations and hire additional sales and support personnel.
• Renew the Manufacturing Supply Agreement with Intercon Chemical Company in Fiscal 2026.

Key Dates

Recommendation

The company's auditors have expressed 'substantial doubt about its ability to continue as a going concern,' a critical red flag for investors. Despite a modest increase in net product sales, the company reported a net loss of $2.4 million and consumed $2.015 million in cash from operations in FY2025, leaving a dangerously low cash balance of $334,000. This indicates a persistent inability to generate sustainable profits or positive cash flow. The heavy and increasing reliance on convertible debt from related parties, particularly a single board member, highlights severe liquidity issues and a lack of broader market confidence in its financing. The significant stockholders' deficiency further underscores its precarious financial health. While the SDC technology has potential, the company's current financial instability, high operational risks, customer concentration, and regulatory hurdles (e.g., USDA OLR approval) make it a highly speculative and risky investment. The 'penny stock' designation and OTCQB listing also limit liquidity and market appeal. A seasoned investor would likely view these factors as overwhelmingly negative, suggesting a strong sell recommendation to avoid further capital erosion.

Keywords

PURE Bioscience, SDC, Silver Dihydrogen Citrate, antimicrobial, food safety, PURE Hard Surface, PURE Control, disinfectant, sanitizer, food processing, personal care, EPA, FDA, USDA, Health Canada, OTCQB, convertible notes, going concern, intellectual property, biotechnology, financial reporting